Pheburane® (sodium phenylbutyrate) coverage to reach ~80% of commercially insured US patients by January 1st, 2024

<p>Pheburane® (sodium phenylbutyrate) coverage to reach ~80% of commercially insured US patients in 2024 Medunik USA is pleased to announce that as of January 1st, 2024, Pheburane® (sodium phenylbutyrate) will be covered by commercial plans representing ~80% of the US population. PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) &#8212; Medunik USA (member of Duchesnay Pharmaceutical [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/pheburane-sodium-phenylbutyrate-coverage-to-reach-80-of-commercially-insured-us-patients-by-january-1st-2024/">Pheburane® (sodium phenylbutyrate) coverage to reach ~80% of commercially insured US patients by January 1st, 2024</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>